Aimovig erenumab logo
Neuroscience
AIMOVIG® (erenumab)
Kesimpta ofatumumab logo
Neuroscience
KESIMPTA®▼ (ofatumumab)
Mayzent siponimod logo
Neuroscience
MAYZENT®▼ (siponimod)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.